← The Wire
NMRANasdaq
Neumora Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1885522
Neumora develops novel treatments for brain diseases through a fundamentally different approach to drug development
⚡ Elevated coverage
$330M
Market cap
$1.72
Last close
+4.9%
1D
+12.4%
5D
1.7M
Volume
Price · last 39 sessions-25.5%
May 4L $0.91 · H $2.33Jun 29
56
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · New Debt / ObligationJun 15, 20268-KShareholder VoteMay 29, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 17, 2026DEF 14ADEF 14AApr 17, 2026SC 13D/ASC 13D/AApr 1, 202610-K10-KMar 30, 20268-KResults of OperationsMar 30, 20268-KReg FD DisclosureFeb 11, 20268-KReg FD DisclosureJan 12, 20268-KCompany UpdateJan 5, 20268-KEquity IssuanceNov 21, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KCompany UpdateOct 27, 20258-KCompany UpdateOct 27, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KShareholder VoteMay 30, 2025DEFA14ADEFA14AMay 16, 20258-KDelisting NoticeMay 16, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 20258-K/AExecutive ChangeApr 11, 202510-K10-KMar 3, 20258-KResults of OperationsMar 3, 20258-K/AExecutive ChangeFeb 21, 20258-KExecutive Change · Reg FD DisclosureFeb 13, 20258-KReg FD DisclosureJan 13, 20258-KCompany UpdateJan 2, 2025SC 13GSC 13GNov 12, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KShareholder VoteJun 14, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 20248-KCompany UpdateApr 15, 202410-K10-KMar 7, 20248-KResults of OperationsMar 7, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GFeb 13, 20248-KReg FD DisclosureJan 8, 20248-KCompany UpdateNov 28, 202310-Q10-QNov 1, 20238-KResults of OperationsNov 1, 2023SC 13DARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13DOct 2, 20238-KBylaw Amendment · Company UpdateSep 19, 2023424B4424B4Sep 18, 2023S-1/AS-1/ASep 11, 2023S-1S-1Aug 25, 2023
Insider Activity
In the 90 days to Feb 17, 2026: 4 sold $83K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 17, 2026 | Berns Paul LSee Remarks | Sell | 9,819 | $3.51 | $34K |
| Feb 17, 2026 | Aurora Daljit SinghSee Remarks | Sell | 6,165 | $3.56 | $22K |
| Feb 17, 2026 | Pinto JoshuaPresident | Sell | 5,967 | $3.54 | $21K |
| Feb 17, 2026 | Milligan Michael LeeSee Remarks | Sell | 1,436 | $3.57 | $5K |
| Nov 11, 2025 | Aurora Daljit SinghSee Remarks | Sell | 114,703 | $2.68 | $307K |
| Oct 27, 2025 | Burow KristinaDirector,TenPercentOwner | Buy | 1,915,700 | $2.61 | $5.0M |
| Oct 27, 2025 | Arch Venture Partners Xii, LlcTenPercentOwner | Buy | 1,915,700 | $2.61 | $5.0M |
| Oct 27, 2025 | Arch Venture Partners Viii, LlcTenPercentOwner | Buy | 1,915,700 | $2.61 | $5.0M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 3 reputable articles · skews ▼ negative.
Financial TimesNMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations – Company Announcement - FT.com12d agoMorningstarNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)13d agoReutersNeumora scraps depression drug development after repeated trial failures14d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance